Filing Details
- Accession Number:
- 0001209191-19-000406
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-01-02 17:56:56
- Reporting Period:
- 2018-12-28
- Accepted Time:
- 2019-01-02 17:56:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1346830 | Cara Therapeutics Inc. | CARA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1597152 | Ph.d. Frederique Menzaghi | C/O Cara Therapeutics, Inc. 4 Stamford Plaza, 107 Elm St, 9Th Floor Stamford CT 06902 | Sr Vp-Research & Development | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-12-28 | 4,300 | $12.53 | 146,479 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person.
- Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.50 to $12.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Billionaire Hedge Funds
